{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:54:13Z","timestamp":1788648853877,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can be used effectively and safely in kidney transplant (KT) recipients with pretransplant type 2 diabetes as the primary cause of end-stage renal disease (ESRD) remains unclear. In this study, we retrospectively analyzed the efficacy and safety of SGLT2 inhibitors compared with other oral hypoglycemic agents (OHAs) in KT recipients with pretransplant type 2 diabetes as the primary cause of ESRD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>In this retrospective, observational, single-center, inverse probability of treatment weighting (IPTW) analysis study, we compared the outcomes of SGLT2 inhibitors (SGLT2 group) and other OHAs (control group) following KT. A total of 85 recipients with type 2 diabetic nephropathy as the major cause of ESRD before KT who were treated at our institute between October 2003 and October 2019 were screened and included. The variables considered for IPTW were recipient age, sex, body mass index, history of cardiovascular disease, ABO incompatibility, insulin therapy, estimated glomerular filtration rate (eGFR), and hemoglobin A1c (HbA1c) at the initiation of additional OHAs. Primary endpoints were changes in HbA1c, body weight, and eGFR 1 y after the initiation of additional OHAs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>After IPTW analysis, there were 26 patients in the SGLT2 group and 59 patients in the control group (n = 85 overall). The body weights were significantly reduced in the SGLT2 group. There was no statistical difference in changes in HbA1c and eGFR. Similarly, there was no significant difference in the incidence of urinary infection, acute rejection, or other side effects between the groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Our findings suggested that SGLT2 inhibitors reduced the body weight of KT recipients and were used safely without increasing side effects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001228","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T07:25:36Z","timestamp":1633591536000},"page":"e772","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Safety and Efficacy of Sodium-glucose Cotransporter 2 Inhibitors in Kidney Transplant Recipients With Pretransplant Type 2 Diabetes Mellitus: A Retrospective, Single-center, Inverse Probability of Treatment Weighting Analysis of 85 Transplant Patients"],"prefix":"10.1097","volume":"7","author":[{"given":"Yu","family":"Hisadome","sequence":"first","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Ohkuma","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Okabe","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"R2-20240805","first-page":"225","article-title":"Annual progress report from the Japanese Renal Transplant Registry: number of renal transplantations in 2019 and follow-up survey. Article in Japanese.","volume":"55","year":"2020","journal-title":"Jpn J Transplant"},{"key":"R3-20240805","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","article-title":"Microvascular and macrovascular complications of diabetes.","volume":"26","author":"Fowler","year":"2008","journal-title":"Clin Diabetes"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1600-6143.2007.02101.x","article-title":"Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes.","volume":"8","author":"Cosio","year":"2008","journal-title":"Am J Transplant"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"e0195566","DOI":"10.1371\/journal.pone.0195566","article-title":"Effect of post-transplant glycemic control on long-term clinical outcomes in kidney transplant recipients with diabetic nephropathy: a multicenter cohort study in Korea.","volume":"13","author":"Kim","year":"2018","journal-title":"PLoS One"},{"key":"R6-20240805","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"R8-20240805","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20240805","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20240805","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-20240805","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus.","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"R12-20240805","article-title":"Impact of pretransplant and new-onset diabetes after transplantation on the risk of major adverse cardiovascular events in kidney transplant recipients: a population-based cohort study.","author":"Lim","journal-title":"Transplantation"},{"key":"R13-20240805","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis.","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"R14-20240805","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"R15-20240805","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan.","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R16-20240805","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant"},{"key":"R17-20240805","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and safety of canagliflozin in kidney transplant patients.","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J Nephrol"},{"key":"R19-20240805","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series.","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"key":"R20-20240805","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2019.11.007","article-title":"Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients.","volume":"52","author":"AlKindi","year":"2020","journal-title":"Transplant Proc"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","article-title":"Use of empagliflozin in recipients of kidney transplant: a report of 8 cases.","volume":"51","author":"Attallah","year":"2019","journal-title":"Transplant Proc"},{"key":"R22-20240805","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety.","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transplant"},{"key":"R23-20240805","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/M20-2470","article-title":"Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association\u2019s Standards of Medical Care in Diabetes Clinical Guideline.","volume":"173","author":"Doyle-Delgado","year":"2020","journal-title":"Ann Intern Med"},{"key":"R24-20240805","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"R25-20240805","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R26-20240805","doi-asserted-by":"crossref","first-page":"e00185","DOI":"10.1002\/edm2.185","article-title":"Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients.","volume":"4","author":"Song","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"Suppl 1","key":"R27-20240805","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MNH.0b013e328360a268","article-title":"Impact of fluid intake in the prevention of urinary system diseases: a brief review.","volume":"22","author":"Lotan","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R28-20240805","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1053\/j.ajkd.2004.04.040","article-title":"Late urinary tract infection after renal transplantation in the United States.","volume":"44","author":"Abbott","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R29-20240805","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R30-20240805","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects.","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R31-20240805","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"R32-20240805","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:07:06Z","timestamp":1722834426000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001228","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]}}}